MucoLife Therapeutics Named Finalist in Nordic Star 2025 Pitch Competition
MucoLife Therapeutics has been selected as one of the finalists in the Nordic Star 2025 Pitch Competition, taking place during Nordic Life Science Days (NLS Days) 2025 in Gothenburg.
On Tuesday, October 14 (10:00–11:00 CET), CEO Thaher Pelaseyed will present MucoLife’s first-in-class inhaled therapy MLT-001, developed to dissolve airway mucus plugs in COPD, cystic fibrosis, and other muco-obstructive lung diseases. The therapy represents a novel approach to restoring lung function in millions of patients suffering from chronic mucus obstruction.
The Nordic Star Pitch Competition highlights some of the most promising early-stage life science companies in the Nordics, offering them a platform to showcase breakthrough innovations to investors and industry leaders.
About NLS Days 2025
Nordic Life Science Days is the largest partnering conference for the life science industry in the Nordics. The 2025 edition takes place in Gothenburg on October 13–14, bringing together biotech, pharma, medtech, and investor communities for two days of networking, pitching, and deal-making.